Power3 Medical Products, Inc. (OTCBB:PWRM.OB) is a leading edge biotechnology company engaged in the early detection, monitoring, and targeting of diseases through the analysis of proteins. This dynamic team utilizes proteomics in the discovery of protein biomarkers, drug pathways, and mechanisms of disease.

PWRM’s business focus is the development of commercial applications for their proprietary technologies. The scientific team is on the leading edge of the proteomics industry through their discovery of protein footprints, pathways, and mechanisms of disease. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer, neurodegenerative disease and drug resistance in cancer. The Company is in a strong competitive position with over 190 identified biomarkers and a state-of-the-art proteomics laboratory.

Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that Vito J. Palombella, Chief Scientific Officer, will present a company overview at the BMO 10th Annual Focus on Health Care Conference on Thursday, August 5, 2010 at 10:45 a.m. EDT in New York City.

Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity’s programs in the inhibition of the Hsp90 chaperone system, the Hedgehog pathway, fatty acid amide hydrolase and PI-3 kinase are evidence of its innovative approach to drug discovery and development.

Pressure BioSciences, Inc. (Nasdaq:PBIO) today announced that Mr. Gregory G. Freitag, Esq. has been unanimously elected to the Company’s Board of Directors, effective Tuesday, July 27, 2010. The Board of Directors increased the number of directors from six to seven with Mr. Freitag filling the newly created additional Class III position. Mr. Freitag’s term of office will expire at the 2011 annual meeting of shareholders.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 14 US and 10 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical and enzymatic reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts in the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

Sign Up for our Free Stock Newsletter at http://www.pennyotcstock.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Our disclaimer (http://pennyotcstock.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations.

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.

Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).